Skip to content

Study · Non-randomized trial · n = 55 · 2022

6 results

Effect of upper gastrointestinal disease on the pharmacokinetics of oral semaglutide in subjects with type 2 diabetes.

Meier JJ, Granhall C, Hoevelmann U, Navarria A, Plum-Moerschel L, Ramesh C, Tannapfel A, Kapitza C

Diabetes, obesity & metabolism17 Jan 2022Cited by 16 (Europe PMC)

PMID34957654 (opens in a new tab)DOI10.1111/dom.14632 (opens in a new tab)PepBankPUB-34957654
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialPharmacokinetics

    In adults with type 2 diabetes, oral semaglutide AUC on day 10 was not significantly different between subjects with and without upper GI disease (ratio 1.18).

    In plain wordsIn adults with type 2 diabetes, oral semaglutide exposure was similar with or without upper stomach and gut disease.

    Peptide
    Semaglutide
    Outcome
    No significant changeSemaglutide AUC 0-24h on day 10
    Study

    n = 55

    Comparator
    Subjects without upper GI disease
    Analysis
    Primary
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    3 mg once daily for 5 days, then 7 mg once daily for 5 days · oral · 10 daysAs given in this study (human).

    Measurements

    AUC0-24h group ratio
    1.18 ratio
    with vs without upper GI disease
    95% CI
    0.8 to 1.75 ratio
    AUC0-24h

    Source sentences

    Summary
    1.18 (95% confidence interval [CI], 0.80, 1.75) for AUC0-24h,day10
    2 context sentences
    Summary · context
    Semaglutide exposure was not statistically significantly different between subjects with and without upper GI disease.
    Summary · context
    In an open-label, parallel-group trial (NCT02877355), subjects aged 18-80 years with type 2 diabetes with mild-to-moderate upper GI disease (N = 36; chronic gastritis [n = 5], gastroesophageal reflux disease [n = 8], and both [n = 23]) or without upper GI disease (N = 19) received oral semaglutide 3…
  2. 02HumanNon-randomized trialPharmacokinetics

    In adults with type 2 diabetes, oral semaglutide maximum concentration was not significantly different between subjects with and without upper GI disease (ratio 1.16).

    In plain wordsIn adults with type 2 diabetes, the peak level of oral semaglutide was similar with or without upper stomach and gut disease.

    Peptide
    Semaglutide
    Outcome
    No significant changeSemaglutide Cmax on day 10
    Study

    n = 55

    Comparator
    Subjects without upper GI disease
    Analysis
    Secondary
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    3 mg once daily for 5 days, then 7 mg once daily for 5 days · oral · 10 daysAs given in this study (human).

    Measurements

    Cmax group ratio
    1.16 ratio
    with vs without upper GI disease
    95% CI
    0.77 to 1.76 ratio
    Cmax

    Source sentences

    Summary
    1.16 (95% CI, 0.77, 1.76) for Cmax .
    2 context sentences
    Summary · context
    Semaglutide exposure was not statistically significantly different between subjects with and without upper GI disease.
    Summary · context
    In an open-label, parallel-group trial (NCT02877355), subjects aged 18-80 years with type 2 diabetes with mild-to-moderate upper GI disease (N = 36; chronic gastritis [n = 5], gastroesophageal reflux disease [n = 8], and both [n = 23]) or without upper GI disease (N = 19) received oral semaglutide 3…
  3. 03HumanNon-randomized trialPharmacokinetics

    In adults with type 2 diabetes, time to maximum concentration of oral semaglutide was similar in subjects with and without upper GI disease.

    In plain wordsIn adults with type 2 diabetes, the time to peak level of oral semaglutide was similar with or without upper stomach and gut disease.

    Peptide
    Semaglutide
    Outcome
    No significant changeTime to Cmax
    Study

    n = 55

    Comparator
    Subjects without upper GI disease
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    3 mg once daily for 5 days, then 7 mg once daily for 5 days · oral · 10 daysAs given in this study (human).

    Source sentences

    Summary
    Time to Cmax and semaglutide half-life were similar in subjects with and without upper GI disease.
    1 context sentence
    Summary · context
    In an open-label, parallel-group trial (NCT02877355), subjects aged 18-80 years with type 2 diabetes with mild-to-moderate upper GI disease (N = 36; chronic gastritis [n = 5], gastroesophageal reflux disease [n = 8], and both [n = 23]) or without upper GI disease (N = 19) received oral semaglutide 3…
  4. 04HumanNon-randomized trialPharmacokinetics

    In adults with type 2 diabetes, the half-life of oral semaglutide was similar in subjects with and without upper GI disease.

    In plain wordsIn adults with type 2 diabetes, how long oral semaglutide stayed in the body was similar with or without upper stomach and gut disease.

    Peptide
    Semaglutide
    Outcome
    No significant changeSemaglutide half-life
    Study

    n = 55

    Comparator
    Subjects without upper GI disease
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    3 mg once daily for 5 days, then 7 mg once daily for 5 days · oral · 10 daysAs given in this study (human).

    Source sentences

    Summary
    Time to Cmax and semaglutide half-life were similar in subjects with and without upper GI disease.
    1 context sentence
    Summary · context
    In an open-label, parallel-group trial (NCT02877355), subjects aged 18-80 years with type 2 diabetes with mild-to-moderate upper GI disease (N = 36; chronic gastritis [n = 5], gastroesophageal reflux disease [n = 8], and both [n = 23]) or without upper GI disease (N = 19) received oral semaglutide 3…
  5. 05HumanNon-randomized trialSafety outcome

    In adults with type 2 diabetes, oral semaglutide was well tolerated and all adverse events were mild-to-moderate.

    In plain wordsIn adults with type 2 diabetes, oral semaglutide was well tolerated and all side effects were mild-to-moderate.

    Peptide
    Semaglutide
    Outcome
    Not applicableSeverity of adverse events
    Study

    n = 55

    Outcome group
    Adverse events · Whole body
    Studied dose
    3 mg once daily for 5 days, then 7 mg once daily for 5 days · oral · 10 daysAs given in this study (human).

    Source sentences

    Summary
    Oral semaglutide was well tolerated; all adverse events were mild-to-moderate
    1 context sentence
    Summary · context
    In an open-label, parallel-group trial (NCT02877355), subjects aged 18-80 years with type 2 diabetes with mild-to-moderate upper GI disease (N = 36; chronic gastritis [n = 5], gastroesophageal reflux disease [n = 8], and both [n = 23]) or without upper GI disease (N = 19) received oral semaglutide 3…
  6. 06HumanNon-randomized trialSafety outcome

    In adults with type 2 diabetes given oral semaglutide, no participants withdrew because of adverse events.

    In plain wordsIn adults with type 2 diabetes given oral semaglutide, nobody left the trial because of side effects.

    Peptide
    Semaglutide
    Outcome
    No significant changeWithdrawals because of adverse events
    Study

    n = 55

    Outcome group
    Adverse events · Whole body
    Studied dose
    3 mg once daily for 5 days, then 7 mg once daily for 5 days · oral · 10 daysAs given in this study (human).

    Source sentences

    Summary
    with no withdrawals because of adverse events.
    1 context sentence
    Summary · context
    In an open-label, parallel-group trial (NCT02877355), subjects aged 18-80 years with type 2 diabetes with mild-to-moderate upper GI disease (N = 36; chronic gastritis [n = 5], gastroesophageal reflux disease [n = 8], and both [n = 23]) or without upper GI disease (N = 19) received oral semaglutide 3…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.